Pfizer: Phase 2b/3 Ritlecitinib Trial Meets Primary Efficacy Endpoint In Alopecia Areata Patients
Drug major Pfizer Inc. (PFE) Wednesday announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata. […]
Continue reading »